RANI Rani Therapeutics Holdings Inc

Price (delayed)

$3.7

Market cap

$186.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.29

Enterprise value

$215.09M

Highlights
The EPS has increased by 3% from the previous quarter and by 2.3% YoY
The net income has grown by 2.6% from the previous quarter
The quick ratio has dropped by 83% year-on-year and by 51% since the previous quarter
The company's equity has shrunk by 76% YoY and by 42% QoQ

Key stats

What are the main financial stats of RANI
Market
Shares outstanding
50.42M
Market cap
$186.56M
Enterprise value
$215.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
25.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$27.91M
EBITDA
-$25.87M
Free cash flow
-$49.48M
Per share
EPS
-$1.29
Free cash flow per share
-$1.9
Book value per share
$0.15
Revenue per share
$0
TBVPS
$2.06
Balance sheet
Total assets
$53.51M
Total liabilities
$38.98M
Debt
$35.41M
Equity
$7.4M
Working capital
$28.02M
Liquidity
Debt to equity
4.79
Current ratio
3.09
Quick ratio
2.96
Net debt/EBITDA
-1.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.9%
Return on equity
-213.7%
Return on invested capital
-33.6%
Return on capital employed
-69.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RANI stock price

How has the Rani Therapeutics Holdings stock price performed over time
Intraday
3.06%
1 week
-1.07%
1 month
-7.5%
1 year
-12.94%
YTD
11.45%
QTD
-2.63%

Financial performance

How have Rani Therapeutics Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.62M
Net income
-$33.08M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 3.9% YoY and by 3.8% from the previous quarter
The net income has grown by 2.6% from the previous quarter

Growth

What is Rani Therapeutics Holdings's growth rate over time

Valuation

What is Rani Therapeutics Holdings stock price valuation
P/E
N/A
P/B
25.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 3% from the previous quarter and by 2.3% YoY
RANI's P/B is 106% above its last 4 quarters average of 12.2
The company's equity has shrunk by 76% YoY and by 42% QoQ

Efficiency

How efficient is Rani Therapeutics Holdings business performance
Rani Therapeutics Holdings's return on equity has shrunk by 157% YoY and by 34% QoQ
The ROA has plunged by 59% YoY and by 13% from the previous quarter
RANI's ROIC is up by 17% YoY but it is down by 6% from the previous quarter

Dividends

What is RANI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RANI.

Financial health

How did Rani Therapeutics Holdings financials performed over time
Rani Therapeutics Holdings's total assets is 37% more than its total liabilities
The quick ratio has dropped by 83% year-on-year and by 51% since the previous quarter
The current ratio has shrunk by 82% YoY and by 51% QoQ
The company's debt to equity has surged by 105% QoQ
The company's equity has shrunk by 76% YoY and by 42% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.